184 related articles for article (PubMed ID: 37462387)
1. Mechanisms of dihydromyricetin against hepatocellular carcinoma elucidated by network pharmacology combined with experimental validation.
Zhang S; Shi YN; Gu J; He P; Ai QD; Zhou XD; Wang W; Qin L
Pharm Biol; 2023 Dec; 61(1):1108-1119. PubMed ID: 37462387
[TBL] [Abstract][Full Text] [Related]
2. Exploring the potential targets of Sanshimao formula for hepatocellular carcinoma treatment by a method of network pharmacology combined with molecular biology.
Yu Q; Chen Z; Liu M; Meng Y; Li X; Li B; Du J
J Ethnopharmacol; 2022 Oct; 297():115531. PubMed ID: 35840058
[TBL] [Abstract][Full Text] [Related]
3. Integrating Network Pharmacology and Bioinformatics to Explore the Effects of Dangshen (
Yu Y; Ding S; Xu X; Yan D; Fan Y; Ruan B; Zhang X; Zheng L; Jie W; Zheng S
Drug Des Devel Ther; 2023; 17():659-673. PubMed ID: 36883114
[TBL] [Abstract][Full Text] [Related]
4. Based on network pharmacology and experiments to explore the underlying mechanism of Mahonia bealei (Fortune) Carrière for treating alcoholic hepatocellular carcinoma.
Zhang N; Zhu Y; Zhang X; Yang K; Yang X; An M; Tian C; Li J
J Ethnopharmacol; 2024 Jan; 318(Pt A):116919. PubMed ID: 37453621
[TBL] [Abstract][Full Text] [Related]
5. An advanced network pharmacology study to explore the novel molecular mechanism of Compound Kushen Injection for treating hepatocellular carcinoma by bioinformatics and experimental verification.
Lu S; Meng Z; Tan Y; Wu C; Huang Z; Huang J; Fu C; Stalin A; Guo S; Liu X; You L; Li X; Zhang J; Zhou W; Zhang X; Wang M; Wu J
BMC Complement Med Ther; 2022 Mar; 22(1):54. PubMed ID: 35236335
[TBL] [Abstract][Full Text] [Related]
6. The potential mechanism of Chebulae Fructus in the treatment of hepatocellular carcinoma on the basis of network pharmacology.
Jiang J; Yang Z; Hou G; Yao X; Jiang J
Ann Hepatol; 2022; 27(4):100701. PubMed ID: 35351639
[TBL] [Abstract][Full Text] [Related]
7. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Zhu M; Shi X; Gong Z; Su Q; Yu R; Wang B; Yang T; Dai B; Zhan Y; Zhang D; Zhang Y
Pharmacol Res; 2020 Aug; 158():104868. PubMed ID: 32407961
[TBL] [Abstract][Full Text] [Related]
8. Active ingredients and molecular targets of
Zheng Y; Ji S; Li X; Feng Q
PeerJ; 2022; 10():e13737. PubMed ID: 35873910
[TBL] [Abstract][Full Text] [Related]
9. Network Pharmacology-Based Approach Combined with Bioinformatic Analytics to Elucidate the Potential of Curcumol against Hepatocellular Carcinoma.
Huang X; Rehman HM; Szöllősi AG; Zhou S
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456457
[TBL] [Abstract][Full Text] [Related]
10. A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling.
Yang AL; Wu Q; Hu ZD; Wang SP; Tao YF; Wang AM; Sun YX; Li XL; Dai L; Zhang J
Toxicol Appl Pharmacol; 2021 Nov; 431():115739. PubMed ID: 34619160
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome profile and its partly verification of human hepatocellular carcinoma cells exposed to Yuzhizi () seed extract.
Xiaoyan F; Mingzhe LI; Long C; Chao L; Wenli LU; Zhiqiang P; Dongwei J; Peike P; Zhaoqin F; Xiaomei L
J Tradit Chin Med; 2022 Dec; 42(6):922-931. PubMed ID: 36378050
[TBL] [Abstract][Full Text] [Related]
12. Integrated System Pharmacology Approaches to Elucidate Multi-Target Mechanism of
Khalid HR; Aamir M; Tabassum S; Alghamdi YS; Alzamami A; Ashfaq UA
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234758
[TBL] [Abstract][Full Text] [Related]
13. The anti-hepatocellular carcinoma effect of Aidi injection was related to the synergistic action of cantharidin, formononetin, and isofraxidin through BIRC5, FEN1, and EGFR.
Lu S; Huang J; Zhang J; Wu C; Huang Z; Tao X; You L; Stalin A; Chen M; Li J; Tan Y; Wu Z; Geng L; Li Z; Fan Q; Liu P; Lin Y; Zhao C; Wu J
J Ethnopharmacol; 2024 Jan; 319(Pt 2):117209. PubMed ID: 37757991
[TBL] [Abstract][Full Text] [Related]
14. Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the
Jiang N; Li H; Sun Y; Zeng J; Yang F; Kantawong F; Wu J
Front Pharmacol; 2021; 12():618522. PubMed ID: 33746755
[No Abstract] [Full Text] [Related]
15. In Silico and In Vitro Studies on the Mechanisms of Chinese Medicine Formula (Yiqi Jianpi Jiedu Formula) in the Treatment of Hepatocellular Carcinoma.
Wu Z; Kang J; Tan W; Wei C; He L; Jiang X; Peng L
Comput Math Methods Med; 2022; 2022():8669993. PubMed ID: 36345477
[TBL] [Abstract][Full Text] [Related]
16. A metabolic data-driven systems pharmacology strategy for decoding and validating the mechanism of Compound Kushen Injection against HCC.
Wang KX; Chen YP; Lu AP; Du GH; Qin XM; Guan DG; Gao L
J Ethnopharmacol; 2021 Jun; 274():114043. PubMed ID: 33753143
[TBL] [Abstract][Full Text] [Related]
17. Systems Network Pharmacology-Based Prediction and Analysis of Potential Targets and Pharmacological Mechanism of
Hu Y; Yang L; Lu Y; Wang Y; Jiang J; Liu Y; Cao Q
Evid Based Complement Alternat Med; 2022; 2022():2116006. PubMed ID: 36193154
[TBL] [Abstract][Full Text] [Related]
18. Systems Pharmacology-Based Identification of Mechanisms of Action of Bolbostemma paniculatum for the Treatment of Hepatocellular Carcinoma.
Wang LL; Liao C; Li XQ; Dai R; Ren QW; Shi HL; Wang XP; Feng XS; Chao X
Med Sci Monit; 2021 Jan; 27():e927624. PubMed ID: 33436534
[TBL] [Abstract][Full Text] [Related]
19. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
Wu WL; Wang WY; Yao WQ; Li GD
Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886
[TBL] [Abstract][Full Text] [Related]
20. Revealing the potential mechanism of Astragalus membranaceus improving prognosis of hepatocellular carcinoma by combining transcriptomics and network pharmacology.
Liu Z; Ma H; Lai Z
BMC Complement Med Ther; 2021 Oct; 21(1):263. PubMed ID: 34663301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
